[DDAVP: alternative to replacement treatment in mild haemophilia A and von Willebrand-Jürgens syndrome (author's transl)].
1-Deamino-8-D-arginine vasopressin (DDAVP), a vasopressin analogue, increases factor VIII levels in plasma. A female carrier of haemophilia A with known bleeding diathesis and markedly reduced factor VIII activity was successfully treated with DDAVP during bilateral Caldwell-Luc's operation for chronic maxillary sinusitis. An estimated 5000 U factor VIII concentrate was calculated to have been saved. DDAVP is the first alternative to replacement therapy in the treatment of moderate and mold forms of haemophilia A and von Willebrand's disease.
D001127:Arginine Vasopressin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D005169:Factor VIII / Q000032:analysis; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D008443:Maxillary Sinus / Q000601:surgery*; D008875:Middle Aged; D012852:Sinusitis / Q000601:surgery*; D014667:Vasopressins / Q000031:analogs & derivatives*; D014842:von Willebrand Diseases / Q000188:drug therapy*
D014667:Vasopressins; D001127:Arginine Vasopressin; D005169:Factor VIII
DDAVP: Alternative zur Substitutionsbehandlung bei leichter Hämophilie A und von-Willebrand-Jürgens-Syndrom.